

Attorney Docket No. 2481.1767
Application No.: 10/014,472

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (Currently Amended): A method of treating ~~or preventing~~ a disorder comprising administering to a subject a therapeutically effective amount of enoxaparin, ~~wherein the disorder displays enhanced activity of at least one of the matrix metalloproteinases selected from the group consisting of neutrophil collagenase (MMP-8), aggrecanase, hADAMTS1, and gelatinase A (MMP-2), wherein the disorder is a degenerative joint disorder, connective tissue disorder, wound healing disturbance, periodontal disorder, disorder of the locomotor system, or disturbance of bone metabolism.~~

Claim 2 (Cancelled).

Claim 3 (Currently Amended): The method of claim 1, wherein the disorder is osteoarthroses, spondyloses, chondrolysis, collagenoses, ~~an inflammatory disorder,~~ immunological or metabolism-related acute or chronic arthritides, arthropathies, or myalgias.

Claim 4 (Previously Presented): The method of claim 1, wherein the enoxaparin is administered by subcutaneous, intraarticular, intraperitoneal or intravenous injection.

Attorney Docket No. 2481.1767
Application No.: 10/014,472

Claim 5 (Previously Presented): The method of claim 4, wherein the enoxaparin is administered by intraarticular injection.

Claim 6 (Currently Amended): The method of claim 1, wherein the enoxaparin is administered at a dose of enoxaparin is from about 5 µg to about 200 mg.

Claim 7 (Currently Amended): The method of claim ~~[[1]]~~ 6, wherein the dose of enoxaparin is from about 10 µg to about 40 mg.

Claim 8 (Previously Presented): The method of claim 1, wherein the enoxaparin is administered rectally, orally, inhalationally, or transdermally.

Claims 9-18 (Cancelled).

Claim 19 (New): A method of preventing the recurrence of a disorder comprising administering to a subject a therapeutically effective amount of enoxaparin, wherein the disorder is a degenerative joint disorder, connective tissue disorder, wound healing disturbance, disorder of the locomotor system, or disturbance of bone metabolism.

Claim 20 (New): The method of claim 19, wherein the disorder is osteoarthritis, spondylosis, chondrolysis, collagenosis, immunological or metabolism-related acute or chronic arthritides, arthropathies, or myalgias.

Attorney Docket No. 2481.1767
Application No.: 10/014,472

Claim 21 (New): The method of claim 19, wherein the enoxaparin is administered by subcutaneous, intraarticular, intraperitoneal or intravenous injection.

Claim 22 (New): The method of claim 21, wherein the enoxaparin is administered by intraarticular injection.

Claim 23 (New): The method of claim 19, wherein the enoxaparin is administered at a dose of from about 5 μ g to about 200 mg.

Claim 24 (New): The method of claim 23, wherein the dose of enoxaparin is from about 10 μ g to about 40 mg.

Claim 25 (New): The method of claim 19, wherein the enoxaparin is administered rectally, orally, inhalationally, or transdermally.